Folate-functionalized chitosan nanocarriers of an iron nitrosyl nitric oxide donor for dual antileukemic and antibacterial activity in acute myeloid leukemia cells

Acute myeloid leukemia (AML) treatment is frequently complicated by severe bacterial infections resulting from chemotherapy-induced neutropenia, creating a need for therapeutic platforms that address both leukemic progression and infection-related complications. In this study, folate-functionalized chitosan nanocarriers loaded with an iron nitrosyl nitric oxide donor, FA-CS@FeNOTSP, were developed as a dual-action platform for antileukemic and antibacterial evaluation. The nanocarriers were obtained by carbodiimide-mediated folate conjugation followed by FeNOTSP encapsulation and characterized by FT-IR, UV–Vis spectroscopy, zeta-potential analysis, scanning electron microscopy, and dynamic light scattering. FA-CS@FeNOTSP exhibited high encapsulation efficiency (approximately 85–92%), SEM-derived particle dimensions of approximately 210 nm, hydrodynamic diameters of approximately 250–327 nm in aqueous suspension, and a marked surface-charge shift consistent with folate functionalization. The formulation showed pH/GSH-responsive release, with limited FeNOTSP liberation under physiological conditions (approximately 20% at pH 7.4 after 24 h) and enhanced release under acidic, reductive conditions (approximately 40% at pH 4.5 with 10 mM GSH). DNA-binding and stopped-flow studies indicated moderate ctDNA interaction (K b = 4.31 × 10 4 M − 1 ) through a reversible two-step mechanism involving rapid electrostatic association followed by slower structural binding. FA-CS@FeNOTSP displayed low hemolytic activity (< 1%), reduced cytotoxicity toward WI38 fibroblasts (IC 50 =162.07 ± 1.89 µg mL − 1 ), retained activity against Kasumi-1 AML cells (IC 50 = 84.99 ± 1.11 µg mL − 1 ), and exerted broad-spectrum antibacterial effects (21–32 mm inhibition zones, comparable to gentamicin). Pre-exposure of Kasumi-1 cells to excess free folic acid increased the IC 50 of FA-CS@FeNOTSP by 35.4%, providing preliminary functional support for the contribution of folate-sensitive cellular interactions to the in-vitro response. Collectively, these findings support FA-CS@FeNOTSP as an in-vitro proof-of-concept multifunctional platform with responsive release, antileukemic activity, and antibacterial effects.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-18
DOI
https://doi.org/10.1038/s41598-026-75606-w
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Folate-functionalized chitosan nanocarriers of an iron nitrosyl nitric oxide donor for dual antileukemic and antibacterial activity in acute myeloid leukemia cells

Shaban Y. Shaban, Fawzya I. Elshami, Dalia M. Dowidar, Ibrahim M. Elmehasseb
1 links
Scientific Reports
Nanoparticle-Based Drug Delivery
article

Folate-functionalized chitosan nanocarriers of an iron nitrosyl nitric oxide donor for dual antileukemic and antibacterial activity in acute myeloid leukemia cells

Shaban Y. Shaban, Fawzya I. Elshami, Dalia M. Dowidar, Ibrahim M. Elmehasseb
article en

Abstract

Acute myeloid leukemia (AML) treatment is frequently complicated by severe bacterial infections resulting from chemotherapy-induced neutropenia, creating a need for therapeutic platforms that address both leukemic progression and infection-related complications. In this study, folate-functionalized chitosan nanocarriers loaded with an iron nitrosyl nitric oxide donor, FA-CS@FeNOTSP, were developed as a dual-action platform for antileukemic and antibacterial evaluation. The nanocarriers were obtained by carbodiimide-mediated folate conjugation followed by FeNOTSP encapsulation and characterized by FT-IR, UV–Vis spectroscopy, zeta-potential analysis, scanning electron microscopy, and dynamic light scattering. FA-CS@FeNOTSP exhibited high encapsulation efficiency (approximately 85–92%), SEM-derived particle dimensions of approximately 210 nm, hydrodynamic diameters of approximately 250–327 nm in aqueous suspension, and a marked surface-charge shift consistent with folate functionalization. The formulation showed pH/GSH-responsive release, with limited FeNOTSP liberation under physiological conditions (approximately 20% at pH 7.4 after 24 h) and enhanced release under acidic, reductive conditions (approximately 40% at pH 4.5 with 10 mM GSH). DNA-binding and stopped-flow studies indicated moderate ctDNA interaction (K b = 4.31 × 10 4 M − 1 ) through a reversible two-step mechanism involving rapid electrostatic association followed by slower structural binding. FA-CS@FeNOTSP displayed low hemolytic activity (< 1%), reduced cytotoxicity toward WI38 fibroblasts (IC 50 =162.07 ± 1.89 µg mL − 1 ), retained activity against Kasumi-1 AML cells (IC 50 = 84.99 ± 1.11 µg mL − 1 ), and exerted broad-spectrum antibacterial effects (21–32 mm inhibition zones, comparable to gentamicin). Pre-exposure of Kasumi-1 cells to excess free folic acid increased the IC 50 of FA-CS@FeNOTSP by 35.4%, providing preliminary functional support for the contribution of folate-sensitive cellular interactions to the in-vitro response. Collectively, these findings support FA-CS@FeNOTSP as an in-vitro proof-of-concept multifunctional platform with responsive release, antileukemic activity, and antibacterial effects.

Scientific ReportsVol. 16(1)
Kafrelsheikh University (EG)
Science and Technology Development Fund
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon